| Rheumatoid Arthritis Biologic Competitors Shelled Out $195 Million ... | | Posted Thursday, December 28, 2006 1:21:08 PM by Blog57 Team | | WALTHAM, Mass., Dec. 27 /PRNewswire/ -- Decision Resources and Millennium Research Group have produced a new report that finds that the six companies with approved rheumatoid arthritis (RA) biologics in 2005 (Amgen, Wyeth, Centocor, Schering-Plough, Abbott, and BMS) doled out $195 million promoting the five biologics that were approved for RA at the time (Enbrel, Remicade, Humira, Kineret, and Orencia). The new report entitled Brands & Strategies: Rheumatoid Arthritis finds that the $195 million includes spending for physician detailing and journal advertising in the United States, France, and Germany, as well as direct-to-consumer advertising in the United States. The $195 million spent to promote these brands is substantial and in the range of promotional spending typically associated with more highly prevalent conditions such as dyslipidemia, asthma, and allergic rhinitis.... | |
| |
| | | Can-Fite Presents Results Showing a Correlation Between High Expression of the Receptor Target for Its Drug CF101 and | | Posted Sunday, November 12, 2006 7:19:04 PM by Blog57 Team | | Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, presents results showing a correlation between high expression of the receptor target for its drug CF101 the response of rheumatoid arthritis patients to treatment with the drug. These findings were obtained through analysis of the results of a phase IIa clinical trial in patients with rheumatoid arthritis (RA), and constitute substantial evidence for a correlation between the expression of the A3 adenosine receptor, the target for CF101, developed by Can-Fite, and response of patients to treatment with this drug. These findings will be presented at the annual scientific meeting of the American College of Rheumatology (ACR), which is considered one of the most prominent gatherings in the field of rheumatology.... | |
| |
| | | XOMA Designated As a Subcontractor in 5-Year NIAID Effort to Develop Therapeutic Agents | | Posted Wednesday, November 08, 2006 7:17:51 PM by Blog57 Team | | XOMA Ltd. (NASDAQ: XOMA) today announced that it has been designated as a subcontractor under a prime contract between SRI International (SRI) of Menlo Park, California, and the National Institute of Allergy and Infectious Diseases (NIAID). XOMA and SRI are negotiating the final terms of the subcontract, which will run for 5 years and is expected to reach as much as $28.1 million. Under the subcontract, XOMA would manufacture a variety of monoclonal antibody therapeutic agents of importance to NIAID. Successful negotiation of the new subcontract would, if the full $28.1 million were funded, bring the total of XOMA's governmental contract awards to approximately $60 million since March of 2005. "This is an important achievement for XOMA, since it highlights the US Government's confidence in the quality of our antibody production capabilities as well as demonstrating the success of our new initiative to serve government clients.... | |
| |
| | | False medical ads in newspapers banned | | Posted Sunday, November 05, 2006 3:40:30 AM by Blog57 Team | | BEIJING: China has moved to combat rampant false medical advertising in newspapers, which account for over half of some publications' ad revenues, state press reported yesterday. The central government introduced a ban on Wednesday for a wide range of medical treatment advertising, including for cancer, venereal diseases, abortions, AIDS, psoriasis, epilepsy and hepatitis B, China Daily said. The ban followed a similar prohibition introduced in August on advertising for breast enlargement products and operations to make people taller. The blanket bans were introduced because many ads for the treatments were false or fictitious, the paper said, adding the move was an effort to improve trust in newspapers. China Daily said the ad bans would hurt almost every newspaper in the country, especially the smaller ones. These ads can account for up to 60% of the revenue of some small newspapers, the paper quoted Chen Gang, a professor of advertising with Peking University, as saying.... | |
| |
| | | Psoriasis: Skin Symptoms May Be Just The Tip Of The Iceburg | | Posted Wednesday, November 01, 2006 1:40:00 PM by Blog57 Team | | World Psoriasis Day will have a more poignant focus this year as the International Psoriasis Council (IPC) issues a 'call to action' to medical experts to elevate psoriasis on the public health agenda by undertaking a more thorough therapeutic approach. Recommendations include the need to review current guidelines to ensure a more holistic approach to the management of psoriasis, taking into account the many potential co-morbidities, to prevent this significant health burden escalating. It is essential that physicians are vigilant about monitoring patients for signs of co-morbid conditions and are educated on all the therapeutic options available. These recommendations come following a collaborative Consensus Meeting convened by the IPC held at the 15th European Academy of Dermatology and Venereology (EADV) Congressearlier this month.... | |
| |
| | | World Psoriasis Day promotes greater understanding of the disease in Singapore | | Posted Wednesday, November 01, 2006 11:31:14 AM by Blog57 Team | | SINGAPORE: Psoriasis patients gathered at the Singapore Management Universitys Campus Green over the weekend for World Psoriasis Day (WPD), where members of the Psoriasis Association of Singapore (PAS) and Wyeth Pharmaceuticals shared their experiences to foster greater understanding of the condition. Through World Psoriasis Day, we want to raise awareness and dispel the myths about the condition, while providing a platform for people with psoriasis to speak up about living with the disease, says Dr. Colin Theng, President, PAS, and Associate Consultant Dermatologist at the National Skin Centre. We also want to equip them with information about improved treatment options, and empower them to improve their quality of life through greater support and understanding. There are some 40,000 people in Singapore who suffer from psoriasis a lifelong skin disease that can cause incapacitating discomfort and distress.... | |
| |
| | | World Psoriasis Day Calls Attention to a Serious Disease | | Posted Saturday, October 28, 2006 11:28:21 AM by Blog57 Team | | They'll be celebrating all over the world with events that run the gamut - from a 5K street walk in Kenya to a roller skating exhibition in Paris. While the activities may seem a bit frivolous, the reason for gathering - to bring public awareness to psoriasis - is as serious as the disease itself. Oct. 29, 2006, marks the third annual World Psoriasis Day, a day dedicated to spreading awareness about psoriasis and giving attention and consideration to those who have the disease-an estimated 125 million people worldwide. World Psoriasis Day is coordinated by the International Federation of Psoriasis Associations (IFPA), a global consortium of psoriasis patient associations from around the world, including the National Psoriasis Foundation, a founding member of IFPA. World Psoriasis Day recognizes the serious nature of psoriasis, a disease often dismissed as merely a cosmetic skin condition.... | |
| |
| | | Psoriasis Cure Now celebrates 'Health Care Advocate of the Year' winners | | Posted Tuesday, October 24, 2006 7:14:46 PM by Blog57 Team | | "Psoriasis Cure Now," a nonprofit patient advocacy group, today announced its 2006 "Health Care Advocates of the Year." The recipients are Congressman Jim Gerlach of Pennsylvania, and Tom and Joy Murdough of the Murdough Foundation of Hudson, Ohio. These three leaders took action to ensure that funding for psoriasis research is increased. Rep. Gerlach worked in bipartisan fashion on efforts urging the National Institutes of Health " /> National Institutes of Health (NIH) to focus more attention on this painful and often debilitating disease. Psoriasis research funding at NIH has lagged behind other research areas. Even as NIH funding doubled over the last decade, psoriasis research funding fell 22%, receiving just $6.5 million last year out of a federal medical research budget approaching $30 billion.... | |
| |
| | | Apollo Develops Topical Treatment for Psoriasis, Eliminating Need for Injections | | Posted Saturday, October 21, 2006 7:09:52 AM by Blog57 Team | | Sydney, Australia, Oct 17, 2006 - (JCN Newswire) - Apollo Life Sciences (ASX: AOP), a Sydney-based biotechnology company, is pleased to announce that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies. The cream-based treatment, which relieves symptoms without an injection, is now proceeding to Phase 2 clinical trials.Apollo developed its proprietary formula using a Tumour Necrosis Factor (TNF) blocker, a protein that reduces inflammation and is used to treat psoriasis and other inflammatory diseases. The trials confirmed that Apollo's 'transdermal' technology successfully delivers large proteins, such as anti-inflammatories, through the skin. In comparison, psoriasis treatment products currently on the market must be injected.Comparative tests found Apollo's product at least as effective as treatments offered by market leaders Enbrel, Humira and Remicade, which dominate a global TNF-blocker market estimated to be worth around US$8.5 billion, with an annual growth rate of over 30%.Apollo's TransD(TM) technology, which takes anti-inflammatories and other substances through the skin, makes possible topical application of medications previously taken via injections or tablets, thus enabling direct treatment of affected areas.... | |
| |
| | | Once Approved for Psoriasis, Physicians Plan to Increase Prescriptions of Abbott Laboratories' Humira at the Expense of | | Posted Tuesday, October 17, 2006 11:20:38 PM by Blog57 Team | | Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds physicians will prescribe Abbott Laboratories' Humira at the expense of Amgen/Wyeth's Enbrel, Genentech's Raptiva, methotrexate, and Centocor/Schering Plough's Remicade upon its expected approval for psoriasis in 2007. According to the new Treatment Algorithm Insight Series report entitled Treatment Algorithms for Psoriasis, physicians suggest that the main factors driving Humira's uptake are its efficacy in clinical trials and its side effect/safety profile. The report also finds that physicians are optimistic about payors making biologics a more cost-effective option. "Forty one percent of dermatologists and 43% of primary care physicians we surveyed believe that in the next two years biologics will be reimbursed at lower copays," said Madhuri Borde, analyst at Decision Resources.... | |
| |
| |
|
|
